Eli Lilly: skin disease study meets primary endpoint
(CercleFinance.com) - Eli Lilly and its research partner Incyte said on Monday that their rheumatoid arthritis drug baricitinib met its primary endpoint in two Phase III trials on atopic dermatitis, a serious form of eczema.
In both trials, adult patients with moderate to severe atopic dermatitis achieved clear - or almost clear - skin compared to patients treated with placebo, the drugmakers said.
Baricitinib is already approved for the treatment of rheumatoid arthritis in over 50 countries, including the US and the EU.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
In both trials, adult patients with moderate to severe atopic dermatitis achieved clear - or almost clear - skin compared to patients treated with placebo, the drugmakers said.
Baricitinib is already approved for the treatment of rheumatoid arthritis in over 50 countries, including the US and the EU.
Copyright (c) 2019 CercleFinance.com. All rights reserved.